Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 16, 2023; San Francisco, CA): Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate in Patients with Advanced Prostate Cancer
Propella Therapeutics, Inc. presented “Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular (IM) Depot Injection of Abiraterone Decanoate in Patients with Advanced Prostate Cancer” at the American Society of Clinical Oncology Genitourinary Symposium on February 16, 2023.
Press Release: Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
Propella Therapeutics, Inc. announced its presentation of updated Phase 1/2a data of PRL-02 (abiraterone decanoate) for the treatment of advanced prostate cancer at the 2023 ASCO Genitourinary (GU) Cancers Symposium on February 16, 2023. PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA. Also, recently issued U.S. patent 11,559,534 expands the PRL-02 IP estate with additional composition of matter and methods of use claims.
Presentation at the European Society for Medical Oncology Congress 2022 (September 11, 2022; Paris, France): Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)
Propella Therapeutics, Inc. presented phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at the European Society for Medical Oncology Congress 2022 in Paris, France on September 11, 2022.
Press Release: Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022
Propella Therapeutics, Inc. announced its presentation of Phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at European Society for Medical Oncology Congress 2022 on September 11, 2022.
Press Release: Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China
Propella Therapeutics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis of the knee.
Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (PRL-02) – Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats
Propella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 17, 2022.
Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation
Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.
Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.
Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation
Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.